WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 29, 2016

proyectovikingo@proyectovikingo.es

Contents

•	• ,	C	CD 1	
П.	1St.	Ωt	Tah	၂၉၄

1	Participant characteristics	:
2	According to Local Recurrence	
3	According to Metastasis	
4	According to Exitus	
5	Incidence by outcome [95% CI]	
List	of Figures	
\mathbf{List}		ŗ
\mathbf{List}	Local Recurrence	
1	Local Recurrence	7
$\begin{array}{c} 1 \\ 2 \end{array}$	Local Recurrence	9
1 2 3	Local Recurrence	7 9 10

Table 1: Participant characteristics

	LL]	Ν
N=	=235	
Age	65.7 (11.4)	235
Sex: Men	$168 \ (71.5\%)$	235
Tumor level:		235
$0\text{-}6\mathrm{cm}$	93~(39.6%)	
$7\text{-}12\mathrm{cm}$	99 (42.1%)	
$13\text{-}15\mathrm{cm}$	43 (18.3%)	
Tumor stage:		235
0	$17 \ (7.23\%)$	
I	88 (37.4%)	
II	50 (21.3%)	
III	80 (34.0%)	
Neoadjuvant treatment	122 (51.9%)	235
Type of resection:		235
Abdominoperineal resecti	on 75 (31.9%)	
Anterior resection	156 (66.4%)	
Hartmann	4 (1.70%)	
Perforation	12 (5.11%)	235
Invasion circumferential margi	in 26 (11.1%)	235
Mesorrecto quality:		235
Satisfactory	214 (91.1%)	
Partial	$10 \ (4.26\%)$	
No-satisfactory	$11\ (4.68\%)$	
Recidive	9(3.83%)	235
Months to recidive	$14.0 \ [3.00; 32.5]$	235
Metastasis	$31\ (13.2\%)$	235
Months to Metastasis	$10.0 \ [3.00;30.0]$	235
Exitus	$32\ (13.6\%)$	235
Months to exitus	$14.0 \ [3.00; 33.5]$	235

Table 2: According to Local Recurrence

			Crude		Multivariat	e	
	No event n= 226	Event n= 9	HR	p-value	HR	p-value	N
Age (10y)	6.59 (1.15)	6.14 (1.03)	0.68 [0.37;1.27]	0.227	0.60 [0.26; 1.37]	0.226	235
Sex: Men	164 (72.6%)	4 (44.4%)	0.35 [0.09; 1.30]	0.117	1.06 [0.12; 9.09]	0.955	235
Tumor level:	(' ' ' ' ' '	(, , , ,	. , 1		. , 1		235
0-6cm	87 (38.5%)	6 (66.7%)	1.42 [0.28; 7.05]	0.670	6.59 [0.36;119.58]	0.202	
7-12cm	98 (43.4%)	1 (11.1%)	0.21 [0.02; 2.37]	0.209	0.10 [0.00; 2.39]	0.154	
Tumor stage:	, ,	, ,					235
0	17 (7.52%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999	
II	47 (20.8%)	3 (33.3%)	7.05 [0.73;67.9]	0.091	7.34 [0.56; 96.34]	0.129	
III	75 (33.2%)	5 (55.6%)	8.00 [0.93;68.6]	0.058	7.58 [0.45;128.68]	0.161	
Neoadjuvant treatment	$118 \ (52.2\%)$	4(44.4%)	$0.95 \ [0.25; 3.54]$	0.939	1.38 [0.17; 11.04]	0.76	235
Type of resection:							235
Abdominoperineal resection	71 (31.4%)	4(44.4%)	1.54 [0.41; 5.75]	0.520	0.11 [0.01; 1.20]	0.07	
Hartmann	4 (1.77%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	0.999	
Perforation	$10 \ (4.42\%)$	2(22.2%)	9.16 [1.89;44.3]	0.006	10.20 [0.61;169.75]	0.105	235
Invasion circumferential margin	22 (9.73%)	4 (44.4%)	4.87 [1.31;18.1]	0.018	2.24 [0.31; 16.13]	0.425	235
Mesorrecto quality:							235
Partial	9 (3.98%)	1~(11.1%)	3.00 [0.37;24.2]	0.301	0.75 [0.03; 18.53]	0.861	
No-satisfactory	11 (4.87%)	0(0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999	

Reference categories:

- Age, a decade
- Sex, Women
- \bullet Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence




Table 3: According to Metastasis

			Crude		Multivaria	ite	
	No event	Event	$_{ m HR}$	p-value	$_{ m HR}$	p-value	N
	n= 204	n= 31					
Age (10y)	6.60 (1.13)	6.40 (1.25)	0.86 [0.61;1.21]	0.389	0.83 [0.59; 1.15]	0.259	235
Sex: Men	151 (74.0%)	17 (54.8%)	0.49 [0.24; 1.00]	0.050	0.83 [0.36; 1.91]	0.655	235
Tumor level:	,	,					235
0-6cm	79 (38.7%)	14 (45.2%)	1.23 [0.44; 3.40]	0.696	1.85 [0.42; 8.16]	0.418	
7-12cm	87 (42.6%)	12 (38.7%)	0.98 [0.35; 2.79]	0.974	0.77 [0.24; 2.49]	0.657	
Tumor stage:							235
0	$16 \ (7.84\%)$	1 (3.23%)	0.89 [0.11; 7.24]	0.913	0.39 [0.03; 4.85]	0.464	
II	45~(22.1%)	5~(16.1%)	1.57 [0.50; 4.96]	0.439	1.77 [0.51; 6.14]	0.371	
III	62 (30.4%)	18 (58.1%)	4.18 [1.74;10.1]	0.001	5.40 [2.01;14.50]	< 0.001	
Neoadjuvant treatment	105~(51.5%)	17 (54.8%)	1.37 [0.68; 2.79]	0.379	1.37 [0.58; 3.22]	0.471	235
Type of resection:							235
Abdominoperineal resection	65 (31.9%)	10 (32.3%)	1.00 [0.46; 2.15]	0.999	0.42 [0.13; 1.42]	0.165	
Hartmann	2~(0.98%)	2(6.45%)	7.78 [1.79;33.9]	0.006	8.92 [0.96;82.98]	0.054	
Perforation	9 (4.41%)	3~(9.68%)	4.05 [1.23;13.4]	0.022	2.83 [0.49;16.40]	0.246	235
Invasion circumferential margin	$21\ (10.3\%)$	5~(16.1%)	1.28 [0.49; 3.34]	0.612	0.56 [0.15; 2.01]	0.371	235
Mesorrecto quality:							235
Partial	6(2.94%)	4~(12.9%)	4.05 [1.41;11.7]	0.010	2.51 [0.60; 10.57]	0.21	
No-satisfactory	10 (4.90%)	1(3.23%)	1.74 [0.24;12.9]	0.586	1.11 [0.09;14.46]	0.934	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- $\bullet~$ Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 2: Metastasis




Table 4: According to Exitus

			Crude		Multivaria	te	
	No event $n=203$	Event n= 32	$_{ m HR}$	p-value	HR	p-value	N
Age (10y)	6.51 (1.13)	6.93 (1.18)	1.52 [1.05;2.21]	0.025	1.34 [0.90; 1.99]	0.155	235
Sex: Men	146 (71.9%)	22 (68.8%)	0.93 [0.44;1.96]	0.846	1.44 [0.58; 3.58]	0.429	235
Tumor level:	,	,	. , ,		. , ,		235
0-6cm	78 (38.4%)	15 (46.9%)	0.92 [0.39; 2.18]	0.851	3.48 [0.71;16.96]	0.123	
7-12cm	90 (44.3%)	9 (28.1%)	0.51 [0.20; 1.33]	0.169	1.06 [0.32; 3.50]	0.92	
Tumor stage:	, ,	, ,			-		235
0	16 (7.88%)	1 (3.12%)	1.01 [0.12; 8.21]	0.995	0.58 [0.04; 9.62]	0.707	
II	43~(21.2%)	7(21.9%)	2.24 [0.79; 6.41]	0.131	2.43 [0.76; 7.82]	0.136	
III	63 (31.0%)	17 (53.1%)	4.57 [1.88;11.1]	0.001	5.56 [2.02;15.29]	< 0.001	
Neoadjuvant treatment	109 (53.7%)	13~(40.6%)	0.78 [0.38; 1.57]	0.482	0.74 [0.30; 1.80]	0.502	235
Type of resection:							235
Abdominoperineal resection	63 (31.0%)	12 (37.5%)	1.22 [0.59; 2.52]	0.584	0.37 [0.10; 1.33]	0.127	
Hartmann	3~(1.48%)	1 (3.12%)	7.09 [0.89;56.2]	0.064	2.23 [0.12;43.16]	0.596	
Perforation	9(4.43%)	3~(9.38%)	3.19 [0.97;10.5]	0.057	1.05 [0.19; 5.89]	0.955	235
Invasion circumferential margin	18 (8.87%)	8 (25.0%)	1.95 [0.87; 4.35]	0.103	1.34 [0.50; 3.58]	0.559	235
Mesorrecto quality:							235
Partial	8 (3.94%)	2~(6.25%)	2.13 [0.50; 8.99]	0.305	4.17 [0.71;24.43]	0.113	
No-satisfactory	9 (4.43%)	2(6.25%)	3.34 [0.78;14.2]	0.103	7.05 [0.97;51.19]	0.054	

Reference categories:

- Age, a decade
- $\bullet~$ Sex, Women
- \bullet Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$ Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus




Figure 4: Local Recurrence, according to Type of Resection:






Figure 5: Metastasis, according to Type of Resection:




Figure 6: Survival, according to Type of Resection:




Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	1.48 [3.5; 0]	13.03 [18.41; 7.3]	3.34 [5.98; 0.63]
24	6.95 [11.52; 2.15]	21.89 [28.79; 14.31]	15.1 [21.33; 8.39]
36	8.59 [14.01; 2.82]	23.13 [30.28; 15.23]	23.55 [31.46; 14.74]
48	8.59 [14.01; 2.82]	25 [32.75; 16.36]	28.09 [36.81; 18.17]
60	8.59 [14.01; 2.82]	25 [32.75; 16.36]	36.78 [48.13; 22.95]